Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead Sciences

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences

4Q Revenues: $899.2 million (+48%)

4Q Loss: $1.7 billion (earnings were $281.6 million 4Q2005)

FY Revenues: $3 billion (+49%)

FY Loss: $1.2 billion (earnings were $813 million FY2005)

Comments: Record sales in the quarter and FY were primarily driven by the company’s HIV product franchise of Truvada, Viread and Emtriva, including the strong uptake of Atripla following its July 2006 launch in the U.S. HIV product sales were $642.4 million in the quarter, up 67% and $2.1 billion for the year, up 52%. Hepsera sales were $65.9 million for the quarter, up 29% and $230.5 million for the year, up 24%. Results for the quarter and FY include acquisition-related charges of $2 billion and $2.4 billion, respectively, related to IPR&D programs acquired from Corus and Myogen. R&D expenses for the quarter were $111.6 million compared to $68.8 million in 4Q2005. For the year R&D expenses were $383.9 million compared to $277.7 million FY2005.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters